Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Recent Advances in Non-Small Cell Lung Cancer Targeted Therapy; an Update Review Publisher



Araghi M1 ; Mannani R2 ; Heidarnejad Maleki A3 ; Hamidi A4 ; Rostami S3 ; Safa SH3 ; Faramarzi F5 ; Khorasani S6 ; Alimohammadi M7 ; Tahmasebi S8 ; Akhavansigari R9, 10
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pathology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
  2. 2. Vascular Surgeon, Department of Surgery, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
  3. 3. School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
  4. 4. Razi Vaccine and Serum Research Institute, Arak Branch, karaj, Iran
  5. 5. Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
  6. 6. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  8. 8. Student Research Committee, Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  9. 9. Department of Neurosurgery, University Medical Center, Tuebingen, Germany
  10. 10. Department of Health Care Management and Clinical Research, Collegium Humanum Warsaw Management University Warsaw, Warsaw, Poland

Source: Cancer Cell International Published:2023


Abstract

Lung cancer continues to be the leading cause of cancer-related death worldwide. In the last decade, significant advancements in the diagnosis and treatment of lung cancer, particularly NSCLC, have been achieved with the help of molecular translational research. Among the hopeful breakthroughs in therapeutic approaches, advances in targeted therapy have brought the most successful outcomes in NSCLC treatment. In targeted therapy, antagonists target the specific genes, proteins, or the microenvironment of tumors supporting cancer growth and survival. Indeed, cancer can be managed by blocking the target genes related to tumor cell progression without causing noticeable damage to normal cells. Currently, efforts have been focused on improving the targeted therapy aspects regarding the encouraging outcomes in cancer treatment and the quality of life of patients. Treatment with targeted therapy for NSCLC is changing rapidly due to the pace of scientific research. Accordingly, this updated study aimed to discuss the tumor target antigens comprehensively and targeted therapy-related agents in NSCLC. The current study also summarized the available clinical trial studies for NSCLC patients. © 2023, BioMed Central Ltd., part of Springer Nature.
Related Docs
View other Related Docs
1. Tumor Immunology, Clinical Immunology (2022)
2. New Insights Into Designing Hybrid Nanoparticles for Lung Cancer: Diagnosis and Treatment, Journal of Controlled Release (2019)
3. Review of the Recent Clinical Trials for Pd-1/Pd-L1 Based Lung Cancer Immunotherapy, Expert Review of Anticancer Therapy (2021)
4. Recent Advances in Immune Checkpoint Therapy in Non-Small Cell Lung Cancer and Opportunities for Nanoparticle-Based Therapy, European Journal of Pharmacology (2021)
5. Biomarkers for Immune Checkpoint Inhibitors, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
6. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)
7. Evaluation of Progression-Free Survival and Overall Survival of Epidermal Growth Factor Receptor-Positive Metastatic Lung Adenocarcinoma Patients Treated With Erlotinib, Medical Journal of the Islamic Republic of Iran (2022)
8. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (15)
Seyed Hamidollah Ghaffari (5)
Other Related Docs
9. Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools, ACS Pharmacology and Translational Science (2023)
10. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
11. Immune Checkpoints and Ncrnas: Pioneering Immunotherapy Approaches for Hematological Malignancies, Cancer Cell International (2024)
12. Antileukemia Activity of Human Natural Killer Cell-Derived Nanomagic Bullets Against Acute Myeloid Leukemia (Aml), International Journal of Hematology-Oncology and Stem Cell Research (2024)
13. Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers, Frontiers in Immunology (2017)
14. Targeting the Pd-1/Pd-L1 Pathway in Glioblastoma Multiforme: Preclinical Evidence and Clinical Interventions, International Immunopharmacology (2021)
15. Molecular Mechanisms Underlying the Action of Carcinogens in Gastric Cancer With a Glimpse Into Targeted Therapy, Cellular Oncology (2022)
16. Immunotherapeutic Targets in Non-Small Cell Lung Cancer, Immunology (2023)
17. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)
18. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
19. A Narrative Review of Tumor-Associated Macrophages in Lung Cancer: Regulation of Macrophage Polarization and Therapeutic Implications, Translational Lung Cancer Research (2021)
20. Immune Checkpoint Inhibitors in Cancer Therapy, Current Oncology (2022)
21. Anti-Tumor Activity of Neratinib, a Pan-Her Inhibitor, in Gastric Adenocarcinoma Cells, European Journal of Pharmacology (2019)
22. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
23. Immunopathology and Immunotherapy for Breast Cancer, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
24. Advanced Therapeutic Modalities in Hepatocellular Carcinoma: Novel Insights, Journal of Cellular and Molecular Medicine (2021)
25. Liquid Biopsy: The Unique Test for Chasing the Genetics of Solid Tumors, Epigenetics Insights (2020)
26. Understanding the Tumor Microenvironment for Effective Immunotherapy, Medicinal Research Reviews (2021)
27. The Erbb Receptor Inhibitor Dacomitinib Suppresses Proliferation and Invasion of Pancreatic Ductal Adenocarcinoma Cells, Cellular Oncology (2019)
28. The C-Met Receptor: Implication for Targeted Therapies in Colorectal Cancer, Tumor Biology (2017)
29. How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer, International Immunopharmacology (2020)
30. The Impact of Epithelial-Mesenchymal Transition (Emt) Induced by Metabolic Processes and Intracellular Signaling Pathways on Chemo-Resistance, Metastasis, and Recurrence in Solid Tumors, Cell Communication and Signaling (2024)
31. Lung Cancer-Associated Brain Metastasis: Molecular Mechanisms and Therapeutic Options, Cellular Oncology (2017)
32. Nanoparticulate Systems for Combination Therapies of Lung Cancer: A Review, Journal of Nanoparticle Research (2025)
33. A Novel Tumor Inhibitory Hybridoma Monoclonal Antibody With Dual Specificity for Her3 and Her2, Current Research in Translational Medicine (2021)
34. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
35. Strategies for Enhancing Intratumoral Spread of Oncolytic Adenoviruses, Pharmacology and Therapeutics (2020)
36. Clinical Potential of Pd-1/Pd-L1 Blockade Therapy for Renal Cell Carcinoma (Rcc): A Rapidly Evolving Strategy, Cancer Cell International (2022)
37. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
38. The Role of Myeloid-Derived Suppressor Cells in Lung Cancer and Targeted Immunotherapies, Expert Review of Anticancer Therapy (2022)
39. A Newly Characterized Potentially Probiotic Strain, Lactobacillus Brevis Mk05, and the Toxicity Effects of Its Secretory Proteins Against Mcf-7 Breast Cancer Cells, Probiotics and Antimicrobial Proteins (2021)
40. Liquid Biopsy in Kidney Tumor, Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)
41. Immune Checkpoint Inhibitors: Review of the Existing Evidence and Challenges in Breast Cancer, Immunotherapy (2021)
42. Harnessing the Power of Exosomes for Diagnosis, Prognosis, and Treatment of Hematological Malignancies, Stem Cell Research and Therapy (2025)
43. Looking Into the Toxicity Potential and Clinical Benefits of Tyrosine Kinase Inhibitors (Tkis), Encyclopedia of Toxicology# Fourth Edition: Volume 1-9 (2023)
44. Functional Characterization and Development of Novel Human Kinase Insert Domain Receptor Chimeric Antigen Receptor T-Cells for Immunotherapy of Non-Small Cell Lung Cancer, European Journal of Pharmaceutical Sciences (2023)
45. Development of a Met-Targeted Single-Chain Antibody Fragment As an Anti-Oncogene Targeted Therapy for Breast Cancer, Investigational New Drugs (2023)
46. Cancer Stem Cells and Oral Cancer: Insights Into Molecular Mechanisms and Therapeutic Approaches, Cancer Cell International (2020)
47. A Review: Fda-Approved Fluorine-Containing Small Molecules From 2015 to 2022, European Journal of Medicinal Chemistry (2023)
48. Negative Prognostic Behaviour of Pd-L1 Expression in Tongue and Larynx Squamous Cell Carcinoma and Its Significant Predictive Power in Combination With Pd-1 Expression on Tils, BMC Immunology (2024)
49. Resistance to Immunotherapy in Human Malignancies: Mechanisms, Research Progresses, Challenges, and Opportunities, Journal of Cellular Physiology (2022)
50. Evaluation of Treatment Response and Survival Outcomes in Anaplastic Thyroid Cancer Patients Following Surgery With and Without Other Treatment Modalities: A Systematic Review, Health Science Reports (2025)